Valneva SE (VALN)Healthcare | Biotechnology | Saint-Herblain, France | NasdaqGS
5.98 USD
-0.06
(-0.993%) ⇩
(April 21, 2026, 1:29 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:40 a.m. EDT
Securities fraud investigation and negative revenue growth create significant near-term downside risk, outweighing the attractive forward P/E. The stock is a distraction-heavy hold rather than a capital-growth play. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.216356 |
| MSTL | 0.216428 |
| AutoARIMA | 0.216839 |
| AutoETS | 0.216865 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 22.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.045 |
| Excess Kurtosis | -1.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 195.208 |
| Revenue per Share | 2.078 |
| Market Cap | 537,097,664 |
| Forward P/E | 7.38 |
| Beta | 1.53 |
| Profit Margins | -65.95% |
| Website | https://valneva.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.113069 |
| Address1 | 6 rue Alain Bombard |
| All Time High | 67.84 |
| All Time Low | 3.62 |
| Ask | 6.1 |
| Ask Size | 33 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 63,580 |
| Average Daily Volume3 Month | 70,144 |
| Average Volume | 70,144 |
| Average Volume10Days | 63,580 |
| Beta | 1.53 |
| Bid | 5.97 |
| Bid Size | 1 |
| Book Value | 1.4451034 |
| City | Saint-Herblain |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.98 |
| Current Ratio | 2.384 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.2 |
| Day Low | 5.965 |
| Debt To Equity | 195.208 |
| Earnings Call Timestamp End | 1,773,864,000 |
| Earnings Call Timestamp Start | 1,773,864,000 |
| Earnings Timestamp | 1,773,837,000 |
| Earnings Timestamp End | 1,773,837,000 |
| Earnings Timestamp Start | 1,773,837,000 |
| Ebitda | -64,702,000 |
| Ebitda Margins | -0.37045 |
| Enterprise To Ebitda | -17.697 |
| Enterprise To Revenue | 6.556 |
| Enterprise Value | 1,145,027,200 |
| Eps Current Year | -1.69 |
| Eps Forward | 0.81 |
| Eps Trailing Twelve Months | -1.6 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 33 2 28 07 37 11 |
| Fifty Day Average | 8.87256 |
| Fifty Day Average Change | -2.8925595 |
| Fifty Day Average Change Percent | -0.32601184 |
| Fifty Two Week Change Percent | -11.3069 |
| Fifty Two Week High | 12.25 |
| Fifty Two Week High Change | -6.27 |
| Fifty Two Week High Change Percent | -0.5118367 |
| Fifty Two Week Low | 5.429 |
| Fifty Two Week Low Change | 0.5510001 |
| Fifty Two Week Low Change Percent | 0.10149201 |
| Fifty Two Week Range | 5.429 - 12.25 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,620,221,400,000 |
| Float Shares | 141,461,897 |
| Forward Eps | 0.81 |
| Forward P E | 7.382716 |
| Free Cashflow | -49,673,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 674 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.10182 |
| Gross Profits | -17,783,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.06001 |
| Implied Shares Outstanding | 89,815,663 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-05-06 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France. |
| Long Name | Valneva SE |
| Market | us_market |
| Market Cap | 537,097,664 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_4550716 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -115,192,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 533,373,501 |
| Number Of Analyst Opinions | 4 |
| Open | 6.2 |
| Operating Cashflow | -52,894,000 |
| Operating Margins | -0.5805 |
| Payout Ratio | 0.0 |
| Phone | 33 2 28 07 37 10 |
| Previous Close | 6.04 |
| Price Eps Current Year | -3.5384614 |
| Price Hint | 2 |
| Price To Book | 4.138112 |
| Price To Sales Trailing12 Months | 3.0751214 |
| Profit Margins | -0.65953004 |
| Quick Ratio | 1.473 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.059999943 |
| Regular Market Change Percent | -0.99337655 |
| Regular Market Day High | 6.2 |
| Regular Market Day Low | 5.965 |
| Regular Market Day Range | 5.965 - 6.2 |
| Regular Market Open | 6.2 |
| Regular Market Previous Close | 6.04 |
| Regular Market Price | 5.98 |
| Regular Market Time | 1,776,792,545 |
| Regular Market Volume | 70,444 |
| Return On Assets | -0.113520004 |
| Return On Equity | -0.80156 |
| Revenue Growth | -0.099 |
| Revenue Per Share | 2.078 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 86,876,549 |
| Shares Percent Shares Out | 0.0018000001 |
| Shares Short | 153,342 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 138,488 |
| Short Name | Valneva SE |
| Short Percent Of Float | 0.0018000001 |
| Short Ratio | 1.28 |
| Source Interval | 15 |
| Symbol | VALN |
| Target High Price | 18.0 |
| Target Low Price | 7.5 |
| Target Mean Price | 12.875 |
| Target Median Price | 13.0 |
| Total Cash | 109,650,000 |
| Total Cash Per Share | 0.632 |
| Total Debt | 207,248,000 |
| Total Revenue | 174,659,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.02309 |
| Two Hundred Day Average Change | -3.0430903 |
| Two Hundred Day Average Change Percent | -0.3372559 |
| Type Disp | Equity |
| Volume | 70,444 |
| Website | https://valneva.com |
| Zip | 44,800 |